• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by XORTX Therapeutics Inc.

    10/22/25 9:24:34 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XRTX alert in real time by email
    6-K 1 tm2529022d2_6k.htm FORM 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of October 2025

     

    Commission File Number:  001-40858

     

    XORTX THERAPEUTICS INC.

    (Translation of registrant’s name into English)

     

    3710 – 33rd Street NW

    Calgary, Alberta T2L 2M1

    Canada

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    x   Form 20-F                      ¨   Form 40-F  

     

     

     

     

     

     

     

    INCORPORATION BY REFERENCE

     

    Exhibits 99.2, 99.3, 99.4 and 99.5 to this report on Form 6-K are hereby incorporated by reference as an Exhibit to the Registration Statement on Form F-3 of XORTX Therapeutics Inc. (File No. 333-269429), as amended and supplemented.

      

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

        XORTX Therapeutics Inc.
        (Registrant)

     

    Date:  October 22, 2025 By: /s/ Allen Davidoff
        Name:    Allen Davidoff
        Title:      President and Chief Executive Officer

     

    Form 6-K Exhibit Index

     

    Exhibit
     Number
      Document Description
    99.1   Press Release of the Registrant, dated October 21, 2025
    99.2   Placement Agency Agreement between D. Boral Capital LLC and XORTX Therapeutics Inc., dated October 21, 2025
    99.3   Form of Securities Purchase Agreement, between XORTX Therapeutics Inc. and Purchaser, dated October 21, 2025
    99.4   Form of Lock-Up Agreement
    99.5   Form of Pre-Funded Common Share Purchase Warrant

     

     

    Get the next $XRTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XRTX

    DatePrice TargetRatingAnalyst
    12/9/2021$11.00Buy
    Alliance Global Partners
    More analyst ratings

    $XRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

    CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 1,746,631 common shares (or common share equivalents in lieu thereof) in a registered direct offering (the "Offering") at a purchase price of US$0.63 per common share. The closing of the Offering is expected to occur on or about October 22, 2025, subject to the satisfaction of customary cl

    10/21/25 8:00:00 AM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

    CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that a press release that had previously been issued on April 17, 2025 was re-issued in error today. Please disregard this prior press release.   XORTX announces that it received today a notice (the "Extension Notice") from the Nasdaq Stock Market LLC ("Nasdaq") granting the Company's request for a 180-day extension to regain compliance with the minimum bid price requirement ("Minimum Bid Requirement")

    10/20/25 8:34:53 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

    CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces receipt of notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the shares to maintain a minimum bid price of US$1.0

    10/20/25 6:45:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on XORTX Therapeutics with a new price target

    Alliance Global Partners initiated coverage of XORTX Therapeutics with a rating of Buy and set a new price target of $11.00

    12/9/21 9:10:32 AM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XRTX
    SEC Filings

    View All

    SEC Form 424B5 filed by XORTX Therapeutics Inc.

    424B5 - XORTX Therapeutics Inc. (0001729214) (Filer)

    10/22/25 9:23:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by XORTX Therapeutics Inc.

    6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

    10/22/25 9:24:34 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by XORTX Therapeutics Inc.

    6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

    10/21/25 9:20:37 AM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XRTX
    Leadership Updates

    Live Leadership Updates

    View All

    XORTX Announces Results of Annual and Special Meeting of Shareholders

    CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the "Meeting") held Thursday, September 12, 2024. A total of 889,288 common shares of the Company were represented at the Meeting, representing approximately 31% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including electi

    9/13/24 7:00:00 AM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XORTX Welcomes New Member to the Board of Directors

    CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv

    4/8/24 7:30:00 AM ET
    $GMDA
    $XRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    XORTX Announces New Clinical Advisory Board Member

    CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease ("ADPKD"), is pleased to announce that Dr. Ronald Perrone has joined the Company's Clinical Advisory Board. Dr. Allen Davidoff stated, "We are excited that Dr. Ron Perrone has agreed to join XORTX's Clinical Advisory Board. Dr. Perrone brings substantial medical and professional experience as a thought leader, combined with clinical experience treating patients with ADPKD and kidney disease. We are privileged

    3/27/24 5:00:00 AM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by XORTX Therapeutics Inc. (Amendment)

    SC 13G/A - XORTX Therapeutics Inc. (0001729214) (Subject)

    2/14/24 3:03:47 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by XORTX Therapeutics Inc.

    SC 13G - XORTX Therapeutics Inc. (0001729214) (Subject)

    2/14/23 1:48:46 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XRTX
    Financials

    Live finance-specific insights

    View All

    XORTX Announces Date for Rescheduled Special Meeting of Shareholders

    CALGARY, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its earlier press release, the special meeting of shareholders has been rescheduled to 10:00 a.m. (Calgary time) on Friday, October 27, 2023 (the "Meeting"). At the Meeting shareholders will consider a consolidation of the Company's issued and outstanding shares in order for the Company to regain compliance with the continued listing requirements for the NASDAQ Capital Market. About XORTX Therap

    10/25/23 5:00:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XORTX Therapeutics Announces Annual and Special Meeting of Shareholders

    CALGARY, Alberta, Nov. 23, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (TSXV:XRTX, NASDAQ:XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces that it will hold its annual and special meeting of shareholders at 11:00 a.m. (Calgary time) on Monday, December 20, 2021 (the "Meeting"). Materials for the Meeting have been mailed to shareholders and are available on the Company's SEDAR profile and the Company's website. The meeting has been called for shareholders to consider annual matters including the election of directors, re-appointment of Smythe LLP Chartered Accountants as au

    11/23/21 7:00:00 AM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care